|
TW201629069A
(zh)
*
|
2015-01-09 |
2016-08-16 |
霍普驅動生物科技股份有限公司 |
參與協同結合之化合物及其用途
|
|
EP4302834A3
(en)
|
2016-07-12 |
2024-07-17 |
Revolution Medicines, Inc. |
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
|
|
JP7240319B2
(ja)
|
2017-01-23 |
2023-03-15 |
レヴォリューション・メディスンズ，インコーポレイテッド |
アロステリックｓｈｐ２阻害剤としての二環式化合物
|
|
KR20190110588A
(ko)
|
2017-01-23 |
2019-09-30 |
레볼루션 메디슨즈, 인크. |
알로스테릭 shp2 억제제로서의 피리딘 화합물
|
|
TW201930292A
(zh)
|
2017-10-12 |
2019-08-01 |
美商銳新醫藥公司 |
作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
|
|
JP7361693B2
(ja)
|
2017-12-15 |
2023-10-16 |
レヴォリューション・メディスンズ，インコーポレイテッド |
アロステリックｓｈｐ２阻害剤としての多環式化合物
|
|
BR112021012057A2
(pt)
*
|
2018-12-21 |
2021-10-19 |
Revolution Medicines, Inc. |
Compostos que participam de ligação cooperativa e usos dos mesmos
|
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202132316A
(zh)
*
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
IL322454A
(en)
*
|
2019-11-04 |
2025-09-01 |
Revolution Medicines Inc |
ras inhibitors
|
|
US20210322405A1
(en)
*
|
2020-04-15 |
2021-10-21 |
Washington University |
Compositions and methods for treating cancer
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2022133037A1
(en)
*
|
2020-12-17 |
2022-06-23 |
Blossomhill Therapeutics, Inc. |
Macrocycles and their use
|
|
CN116635076A
(zh)
*
|
2020-12-17 |
2023-08-22 |
荣山医药股份有限公司 |
大环化合物及其用途
|
|
MX2023011608A
(es)
*
|
2021-04-02 |
2023-12-14 |
Massachusetts Gen Hospital |
Metodos para inhibir ras.
|
|
US20240217960A1
(en)
*
|
2021-04-09 |
2024-07-04 |
Universität Basel |
Triazine derivative as covalent inhibitors of pi3k
|
|
KR20240017811A
(ko)
*
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ｒａｓ阻害剤及びその使用
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
AU2022281343A1
(en)
|
2021-05-25 |
2023-11-30 |
Revolution Medicines, Inc. |
Methods for inhibiting ras
|
|
US12280055B2
(en)
|
2021-05-27 |
2025-04-22 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2023015559A1
(en)
*
|
2021-08-13 |
2023-02-16 |
Nutshell Biotech (Shanghai) Co., Ltd. |
Macrocycle compounds as inhibitors of ras
|
|
AR126854A1
(es)
|
2021-08-27 |
2023-11-22 |
Hoffmann La Roche |
Compuestos macrocíclicos para el tratamiento de cáncer
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
CN119212994A
(zh)
|
2021-12-17 |
2024-12-27 |
建新公司 |
作为shp2抑制剂的吡唑并吡嗪化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
CN119156393A
(zh)
*
|
2022-04-25 |
2024-12-17 |
翰森生物有限责任公司 |
环状化合物及其制备方法和医药用途
|
|
JP2025519199A
(ja)
|
2022-06-01 |
2025-06-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のためのハロインドール大環状化合物
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
EP4582426A4
(en)
*
|
2022-09-19 |
2025-12-24 |
Adlai Nortye Biopharma Co Ltd |
PAN-KRAS INHIBITOR COMPOUND
|
|
KR20250085767A
(ko)
|
2022-09-29 |
2025-06-12 |
광조우 조요 파마테크 컴퍼니 리미티드 |
거대고리 유도체 및 이의 적용
|
|
WO2024153028A1
(zh)
*
|
2023-01-20 |
2024-07-25 |
深圳晶蛋生物医药科技有限公司 |
大环类化合物、其药物组合物及其应用
|
|
CN120813588A
(zh)
|
2023-02-14 |
2025-10-17 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的三环化合物
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
CN116284045A
(zh)
*
|
2023-05-18 |
2023-06-23 |
西南交通大学 |
一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法
|
|
KR20260027943A
(ko)
*
|
2023-05-26 |
2026-03-03 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
|
CN116570599B
(zh)
*
|
2023-07-04 |
2023-10-20 |
四川大学华西医院 |
Vs6766联合ly3009120的应用及药物组合物
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025090809A1
(en)
*
|
2023-10-25 |
2025-05-01 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
CN117567483B
(zh)
*
|
2023-11-23 |
2025-10-21 |
济南市中心医院 |
一种通过金催化的不对称环加成反应及动力学拆分合成手性氮杂八元环类化合物的方法
|
|
WO2025162395A1
(zh)
*
|
2024-02-01 |
2025-08-07 |
山东先声生物制药有限公司 |
吲哚衍生物作为ras抑制剂及其应用
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025214350A1
(en)
*
|
2024-04-08 |
2025-10-16 |
Sunrise Oncology (Hong Kong) Limited |
Macrocyclic compounds as ras inhibitors for the treatment of cancer
|
|
WO2025217307A1
(en)
|
2024-04-09 |
2025-10-16 |
Revolution Medicines, Inc. |
Methods for predicting response to a ras(on) inhibitor and combination therapies
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026046393A1
(zh)
*
|
2024-09-02 |
2026-03-05 |
山东先声再明生物制药有限公司 |
吲哚类衍生物的制备及其应用
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|